Heparin-Induced Thrombocytopenia and Thrombosis
Heparin-Induced Thrombocytopenia and Thrombosis is a research topic within Surgery. Science Explorer counts 16k research works in it since 1950. 17.0% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the phenomenon of Heparin-Induced Thrombocytopenia (HIT) and its associated thrombotic complications, particularly in the context of vaccination. The papers cover various aspects including pathogenesis, diagnosis, management, immune response, and the role of anticoagulation therapy in HIT. Additionally, they explore the clinical features and outcomes related to HIT and thrombosis.
- Heparin-Induced Thrombocytopenia
- Thrombosis
- Vaccination
- PF4 Antibodies
- Immune Response
- Anticoagulation Therapy
- Platelet Activation
- Diagnosis
- Management
- Clinical Features
- Research works
- 16k fractional, since 1950
- In the world top 10%
- 2.7k per year above
- Top-10% rate
- 17.0% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +77% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Heparin-Induced Thrombocytopenia and Thrombosis research?
By volume, the United States and China publish the most (800 and 311 works in 2022–2025).
By volume, 2022–2025
- 1 United States 800 works
- 2 China 311 works
- 3 Japan 173 works
- 4 India 153 works
- 5 Italy 136 works
- 6 United Kingdom 135 works
- 7 Germany 124 works
- 8 France 123 works
- 9 Spain 85 works
- 10 Canada 81 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Heparin-Induced Thrombocytopenia and Thrombosis research?
By volume in 2022–2025, McMaster University publishes the most Heparin-Induced Thrombocytopenia and Thrombosis research, followed by Inserm and University of North Carolina at Chapel Hill.
By volume, 2022–2025
- 1 McMaster UniversityCanada 14 works
- 2 InsermFrance 12 works
- 3 University of North Carolina at Chapel HillUnited States 11 works
- 4 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 10 works
- 5 Mayo Clinic in ArizonaUnited States 10 works
- 6 Medical University of ViennaAustria 10 works
- 7 Cleveland ClinicUnited States 10 works
- 8 Harvard UniversityUnited States 8 works
- 9 Universitätsmedizin GreifswaldGermany 8 works
- 10 University College LondonUnited Kingdom 8 works
Who are the leading researchers in Heparin-Induced Thrombocytopenia and Thrombosis?
The most-cited researchers publishing on Heparin-Induced Thrombocytopenia and Thrombosis include Deepak L. Bhatt.
- 1 Deepak L. Bhatt United States 4.2k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Heparin-Induced Thrombocytopenia and Thrombosis research done?
The largest centres of Heparin-Induced Thrombocytopenia and Thrombosis research in 2022–2025 are Beijing (China), London (United Kingdom), Paris (France) and Tokyo (Japan). Among places with at least 20 works in it, it is an unusually large share of all research in Hamilton.
Largest cities, 2022–2025
Where it is the local speciality
- HamiltonCA · 20.8 works11×
Location quotient: how much more of its research is in Heparin-Induced Thrombocytopenia and Thrombosis than the world average.
Where is the best place to study Heparin-Induced Thrombocytopenia and Thrombosis?
Among universities, judged by research, McMaster University, Medical University of Vienna and Chinese Academy of Medical Sciences & Peking Union Medical College score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | McMaster UniversityCanada | 82.7 | 33.1% | 9.0× | 14 | +1.6% |
| 2 | Medical University of ViennaAustria | 67.1 | 29.1% | 10.6× | 10 | -16.3% |
| 3 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 39.5 | 12.3% | 3.5× | 10 | +64.4% |
| 4 | Harvard UniversityUnited States | 29.9 | 16.5% | 2.1× | 8 | +23.2% |
| 5 | University of North Carolina at Chapel HillUnited States | 18.6 | 2.0% | 2.1× | 11 | +25.7% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Heparin-Induced Thrombocytopenia and Thrombosis research growing?
Output in 2018–2022 was 77% higher than in 2013–2017, peaking in 2022. The fastest-growing topics are Heparin-Induced Thrombocytopenia and Thrombosis.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.